- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02440815
Multimodal MRI Characteristics of Psychotherapy Response in Late Life Depression (PRS)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study procedures include: 1) Telephone screen, 2) Diagnostic evaluation to determine diagnosis of MDD, 3) Baseline evaluation consisting of medical history, cognitive assessment, and MRIs, 4) Participation in 12 weeks of psychotherapy treatment with assessments of depression severity, and 5) Follow up evaluation at 12 weeks consisting of depression, cognitive function, and post treatment MRIs.
Telephone Screen: Older adults who respond to our recruitment efforts for LLD will be screened by telephone using the Patient Health Questionnaire (PHQ-9) and those who obtain a score of 5 or greater will be scheduled for an eligibility appointment within a week of screening. Anyone who endorses the suicide question (item 9) of the PHQ-9 will be scheduled for a same day appointment, and will be seen by the study investigators. Similarly, other exclusion criteria will be assessed using a structured questionnaire. If participants are interested in other treatment referrals these will be provided.
Diagnostic Evaluation: In this assessment, the investigators consent participants and administer measures that address eligibility [i.e., Structured Clinical Interview for Diagnosis of DSM-IV Disorders (SCID)], the 24 item HDRS, Mini Mental Status Exam (MMSE), Clinical Dementia Rating Scale (CDR). To qualify, LLD participants must obtain a diagnosis of MDD (SCID), have an HDRS score of 20 or higher, a MMSE score of 25 or better, and a CDR of 0.5 or less.. Those who do not qualify for the study and/or who are interested in alternate LLD treatments will be offered referrals for services at the outpatient clinics at UCSF or community resources.
Baseline Assessment: After completion of the diagnostic evaluation and being deemed study eligible, LLD participants will be scheduled for a baseline assessment. At the baseline assessment meeting, the HDRS is administered again to confirm depression severity. The baseline assessment consists of 1) demographics and patient characteristics, 2) neuropsychological testing, and 3) depression and functional outcome measures, and 4) multimodal MRI evaluation.
Participant Characteristics: Demographic data, such as age, gender, race, living conditions, marital status, occupation, and education will be obtained as well as previous psychiatric treatment received. Medical comorbidity will be assessed using the Charlson Comorbidity Index (CCI). Medication use will be assessed using the Alzheimer's Disease Neuroimaging Initiative (ADNI) medication history form. Suicidal ideation will be assessed utilizing the Scale for Suicidal Ideation (SSI). The investigators will utilize a clinician rated measures of lifetime history of depressive episodes and depression treatments, the Duke Social Support Index, and the Functional Activities Questionnaire (FAQ) for exploratory analyses.
Cognitive Functioning: Primary cognitive outcome variables will include: the Digit Symbol Substitution Test, the Boston Naming test, and the Rey Auditory Verbal Learning Test as a measure of memory.
Psychotherapeutic Treatment: Problem Solving Therapy (PST) is a brief evidence based psychotherapy that is commonly utilized for treatment of LLD. The problem solving therapy includes 12 weekly in person 50 minute sessions.
Follow up assessments: At 12 weeks, LLD participants will participate in a follow up evaluation that is identical the baseline assessment of depression, cognitive function, and MRI. The investigators will use total HDRS score to determine response to treatment.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
San Francisco, California, United States, 94143
- University of California, San Francisco, Langley Porter Psychiatric Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Current DSM-IV diagnosis of MDD, unipolar type, without psychotic features and 6 weeks minimum duration of current depressive episode.
- Moderate severity of depression using the Hamilton Depression Rating Scale (HDRS > 20).
- English speaking, male or female
- 65 years of age or older
- Good general health
- Able to give informed consent
Exclusion Criteria:
- Antidepressant use or psychotherapy within the past 6 weeks or electroconvulsive therapy within the past 6 months.
- Recent history (<6 months) of substance or alcohol abuse or dependence (DSM-IV criteria).
- Use of cognitive enhancing medications.
- Current diagnosis of Post-Traumatic Stress Disorder or other Axis 1 psychiatric disorder.
- Neurological diseases (e.g., Parkinson's disease, epilepsy, cortical stroke, Alzheimer's disease, traumatic brain injury) or dementia.
- History of surgical procedures affecting study outcomes.
- Contraindications for MR exam, i.e., no claustrophobia, no paramagnetic metal implants, able to fit in the MRI machine comfortably (BMI ≤ 38).
- Acute or uncontrolled medical illness or medication use impacting cognitive function.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Problem Solving Therapy
Problem Solving Therapy (PST) is a brief evidence based psychotherapy that is commonly utilized for treatment of LLD.
The problem solving therapy includes 12 weekly in person 50 minute sessions.
|
Problem Solving Therapy (PST) is a brief evidence based psychotherapy that is commonly utilized for treatment of LLD.
The problem solving therapy includes 12 weekly in person 50 minute sessions.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of change in Cerebral Blood Flow (CBF) as measured by cortical surface-based analysis
Time Frame: Baseline, after 12 weeks of psychotherapy
|
CBF will be measured using multimodal MRI processing (individual 2D pseudo ASL image frames).
We will pursue a cortical surface-based analysis approach which allows for better spatial normalization of cortical data compared to voxel-based approaches.
|
Baseline, after 12 weeks of psychotherapy
|
Rate of change in Cortical Gray Matter (GM) Atrophy as measured by the FreeSurfer image analysis suite
Time Frame: Baseline, after 12 weeks of psychotherapy
|
Cortical Gray Matter Atrophy will be measured using multimodal MRI processing (T1-MRI FreeSurfer image analysis suite version 5.1).
|
Baseline, after 12 weeks of psychotherapy
|
Rate of change in Subcortical White Matter Lesion as measured by WML-T2 FLAIR
Time Frame: Baseline, after 12 weeks of psychotherapy
|
Subcortical White Matter Lesion will be measured using multimodal MRI processing [structural T2-weighted Fluid Attenuated Inversion Recovery (FLAIR)].
|
Baseline, after 12 weeks of psychotherapy
|
Rate of change in Depression Severity as measured by the Hamilton Depression Rating Scale (24 item).
Time Frame: Baseline, after 12 weeks of psychotherapy
|
Baseline, after 12 weeks of psychotherapy
|
|
Rate of change in neuropsychological measures of executive function as measured by the Digit Symbol Substitution Test using total correct
Time Frame: Baseline, after 12 weeks of psychotherapy
|
Baseline, after 12 weeks of psychotherapy
|
|
Rate of change in expressive language as measured by the Boston Naming Test using total correct.
Time Frame: Baseline, after 12 weeks of psychotherapy
|
Baseline, after 12 weeks of psychotherapy
|
|
Rate of change in learning and memory as measured by the Rey Auditory Verbal Learning Test using total correct and delayed recall.
Time Frame: Baseline, after 12 weeks of psychotherapy
|
Baseline, after 12 weeks of psychotherapy
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Scott Mackin, PhD, UCSF Department of Psychiatry
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ROI MH101472
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Major Depressive Disorder
-
Shalvata Mental Health CenterUnknownMAjor Depressive DisorderIsrael
-
York UniversityCentre for Addiction and Mental HealthSuspendedDisorder, Major DepressiveCanada
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDDIndia
-
Gangnam Severance HospitalCompletedMajor Depressive Disorder(MDD)Korea, Republic of
-
University College, LondonCompletedUnipolar Major Depressive DisorderUnited Kingdom
-
Fundació Institut de Recerca de l'Hospital de la...Fondo de Investigacion SanitariaUnknown
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDD)India
-
Repurposed Therapeutics, Inc.Unknown
-
GlaxoSmithKlineCompletedMajor Depressive Disorder (MDD)United States
-
AccexibleRecruitingMajor Depressive Disorder (MDD)Spain
Clinical Trials on Problem Solving Therapy
-
University of WashingtonNational Institute of Mental Health (NIMH)CompletedDepressionUnited States
-
University of OttawaOttawa Hospital Research InstituteActive, not recruiting
-
Washington University School of MedicineNurses for Newborns FoundationCompletedPost-partum DepressionUnited States
-
VA Office of Research and DevelopmentCompletedDepression | AnxietyUnited States
-
University of PittsburghNational Institute of Mental Health (NIMH)CompletedMild Cognitive ImpairmentUnited States
-
Instituto Nacional de Psiquiatría Dr. Ramón de...Universidad Nacional Autonoma de MexicoTerminatedDiabetes Mellitus, Type 2Mexico
-
University of California, San DiegoSan Diego State UniversityCompleted
-
University of PittsburghNational Institute of Mental Health (NIMH)Completed
-
Lawson Health Research InstituteUniversity of Western Ontario, Canada; Queen's UniversityWithdrawn
-
Lawson Health Research InstituteBell Let's Talk Community FundCompleted